AIM

AIM ImmunoTech

AIM

Attention (50-day avg)0%

Attention rank (50-day avg)#2,052

Bullish sentiment (50-day avg)71%

Price to earnings ratio-0.02

Market capitalization7.1M

Earnings per share-0.71

Dividend yield (TTM)—

Revenue (annual)88K

Net income (annual)-14M

Social

What share of all stock conversation is about AIM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 3

$AIM ImmunoTech Inc. is a potential beneficiary of the ongoing Ebola outbreak in Africa, with the company's Ampligen treatment being mentioned as a key candidate in efforts to stop the outbreak.
The current Ebola outbreak in Africa is the largest ever recorded in the Democratic Republic of the Congo, with over 6,000 confirmed cases and a fatality rate of around 48%.
The global estimate of people who have had long COVID is around 400 million, with the risk of post-COVID symptoms being around 1 in 6 or higher in some studies, potentially making Ampligen a significant treatment opportunity.

Generated by AI

Sentiment

Of the messages about AIM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -50	62.5% -26.79	58.42% +2.92
Bearish	—	100% +50	37.5% +26.79	41.58% -2.92

Bullish· Sep 1

The company has secured a major U.S. patent through 2039 for combining Ampligen with Merck's Keytruda, which can trigger a massive 1000%+ squeeze once clinical momentum builds.
The stock has unbelievable news, with a 50% ORR in platinum-sensitive recurrent ovarian cancer, and an expanded collaboration with Merck is expected, which could lead to a 1000% move.
The company has secured long-term IP protection for its immunotherapy combo, with the U.S. patent locked in until 2039, which is a major catalyst for the stock's potential to go above 40 cents a share.

Bearish· Aug 31

The stock has experienced a 58% decline, indicating a significant downward trend.
There are concerns about illegal naked shorting, with some speculating that the news may be a lie or that the company is involved in a scam to steal from retail investors.
The stock's large float manipulation has led to a 20% haircut, despite solid news, suggesting that the market is being manipulated.

Generated by AI

Topics

Of the messages about AIM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	69.57%	42.09%
Technical Analysis	—	—	23.91%	27.5%
Earnings	—	—	0%	3.5%
Controversies	—	—	6.52%	1.46%
Analysts	—	—	0%	7.22%
Macro	—	—	0%	18.23%

Announcements· Jun 1

AIM ImmunoTech has completed enrollment in its Phase 2 DURIPANC trial of Ampligen plus Imfinzi for metastatic pancreatic cancer, achieving the milestone ahead of schedule.
The company is expected to complete the dosing of Ampligen in the Phase 2 DURIPANC trial by mid-June, with primary endpoint evaluation expected in December 2026.
AIM ImmunoTech's lead drug Ampligen has shown promise as a potential treatment for Ebola virus disease, with the company set to release an on-demand video presentation on June 4 detailing pre-clinical findings supporting its use as a prophylactic and/or early-onset antiviral treatment.

Technical Analysis· Jun 1

$AIM is up over 110% on the day, showing massive volume surge, breaking through multiple resistance levels, and trading well above key moving averages.
The stock is forming a bull flag on the hourly chart and has a +30% move with RSI only at 56, holding above VWAP and EMA21, and ADX > 50 indicating a strong trend.
$AIM is approaching the next level of resistance and may experience a dip, with some traders expecting a breakout above $0.60, but others are warning of a potential flush and a broken trend.

Generated by AI

Community

Of the messages about AIM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	34.03%	45.47%
Newcomers	—	50%	65.97%	54.53%

Regulars· Aug 31

The US Patent and Trademark Office (USPTO) has granted AIM ImmunoTech a broad patent covering the use of Ampligen in combination with Pembrolizumab (Keytruda) for cancer treatment, expiring in 2039.
The patent's expiration date of 2039 suggests that AIM's oncology intellectual property (IP) protection will be in place for a significant period, potentially limiting the use of Ampligen in combination with Keytruda for 13 years.
The news has led to a significant short interest in the stock, with some participants suggesting that the low market cap makes it cheaper to buy out AIM than to pay for the use of Ampligen with Keytruda over the next 13 years.

Newcomers· Sep 1

The market is heavily influenced by manipulation and short sellers, but the stock is expected to "fly" and potentially reach prices above $0.5.
The company has big news, including a changing company value and an upcoming collaboration with Merck, which could be a major catalyst for the stock.
The stock has significant potential for a 1000% move, with many believing in its future success and encouraging others to buy in before a major price increase.

Generated by AI

News

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancerSurvival data highlighted in accompanying...

7d agomarkets.businessinsider.com

AIM ImmunoTech Reduces Debt via Equity Exchange Agreements

Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.

18d agoThe Globe and Mail

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued a

20d agoYahoo Finance

Also Discussed

Investors talking about AIM also mention

#	Name	Attention
1	iBio, Inc.IBIO	0%0
2	Cocrystal Pharma, Inc.COCP	0%+0
3	Nanoviricides Inc.NNVC	0%0
4	Co-Diagnostics Inc.CODX	0%+0
5	BIMI - BIMI International Medical Inc.	——
6	HTBX - Heat Biologics, Inc.	——
7	Aytu BioPharma, Inc.AYTU	0%0
8	GHSI - Guardion Health Sciences, Inc.	——
9	OPGN - OpGen, Inc.	——
10	CARM - Carisma Therapeutics, Inc.	——

AIM ImmunoTech Inc.

Healthcare
Biotechnology

AIM ImmunoTech Inc. is a biopharmaceutical company specializing in immunology-focused drug development. The company concentrates on researching and developing therapeutics for multiple types of cancers, viral diseases, immune disorders, and immune-deficiency conditions, addressing areas where existing treatment options are limited or inadequate. AIM ImmunoTech’s work centers on modulating the immune system, with a particular emphasis on leveraging innate immune pathways. Its lead product, Ampligen (rintatolimod), is a double-stranded RNA immunomodulator being developed for use in oncology, viral infections, and immune-related disorders. Another key product, Alferon N Injection (interferon alfa), is a purified, natural-source alpha interferon indicated for certain viral conditions. AIM ImmunoTech operates primarily in the healthcare and biotechnology sector in the United States and collaborates with clinical and academic partners to advance its programs. Founded in 1966 and headquartered in Ocala, Florida, the company plays a niche role in the immuno-pharma segment by focusing on immune-based therapeutic approaches.

Website

Location

2117 SW Highway 484

Ocala, FL, 34473

United States

Social

What share of all stock conversation is about AIM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 3

$AIM ImmunoTech Inc. is a potential beneficiary of the ongoing Ebola outbreak in Africa, with the company's Ampligen treatment being mentioned as a key candidate in efforts to stop the outbreak.
The current Ebola outbreak in Africa is the largest ever recorded in the Democratic Republic of the Congo, with over 6,000 confirmed cases and a fatality rate of around 48%.
The global estimate of people who have had long COVID is around 400 million, with the risk of post-COVID symptoms being around 1 in 6 or higher in some studies, potentially making Ampligen a significant treatment opportunity.

Generated by AI

Sentiment

Of the messages about AIM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -50	62.5% -26.79	58.42% +2.92
Bearish	—	100% +50	37.5% +26.79	41.58% -2.92

Bullish· Sep 1

The company has secured a major U.S. patent through 2039 for combining Ampligen with Merck's Keytruda, which can trigger a massive 1000%+ squeeze once clinical momentum builds.
The stock has unbelievable news, with a 50% ORR in platinum-sensitive recurrent ovarian cancer, and an expanded collaboration with Merck is expected, which could lead to a 1000% move.
The company has secured long-term IP protection for its immunotherapy combo, with the U.S. patent locked in until 2039, which is a major catalyst for the stock's potential to go above 40 cents a share.

Bearish· Aug 31

The stock has experienced a 58% decline, indicating a significant downward trend.
There are concerns about illegal naked shorting, with some speculating that the news may be a lie or that the company is involved in a scam to steal from retail investors.
The stock's large float manipulation has led to a 20% haircut, despite solid news, suggesting that the market is being manipulated.

Generated by AI

Topics

Of the messages about AIM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	69.57%	42.09%
Technical Analysis	—	—	23.91%	27.5%
Earnings	—	—	0%	3.5%
Controversies	—	—	6.52%	1.46%
Analysts	—	—	0%	7.22%
Macro	—	—	0%	18.23%

Announcements· Jun 1

AIM ImmunoTech has completed enrollment in its Phase 2 DURIPANC trial of Ampligen plus Imfinzi for metastatic pancreatic cancer, achieving the milestone ahead of schedule.
The company is expected to complete the dosing of Ampligen in the Phase 2 DURIPANC trial by mid-June, with primary endpoint evaluation expected in December 2026.
AIM ImmunoTech's lead drug Ampligen has shown promise as a potential treatment for Ebola virus disease, with the company set to release an on-demand video presentation on June 4 detailing pre-clinical findings supporting its use as a prophylactic and/or early-onset antiviral treatment.

Technical Analysis· Jun 1

$AIM is up over 110% on the day, showing massive volume surge, breaking through multiple resistance levels, and trading well above key moving averages.
The stock is forming a bull flag on the hourly chart and has a +30% move with RSI only at 56, holding above VWAP and EMA21, and ADX > 50 indicating a strong trend.
$AIM is approaching the next level of resistance and may experience a dip, with some traders expecting a breakout above $0.60, but others are warning of a potential flush and a broken trend.

Generated by AI

Community

Of the messages about AIM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	34.03%	45.47%
Newcomers	—	50%	65.97%	54.53%

Regulars· Aug 31

The US Patent and Trademark Office (USPTO) has granted AIM ImmunoTech a broad patent covering the use of Ampligen in combination with Pembrolizumab (Keytruda) for cancer treatment, expiring in 2039.
The patent's expiration date of 2039 suggests that AIM's oncology intellectual property (IP) protection will be in place for a significant period, potentially limiting the use of Ampligen in combination with Keytruda for 13 years.
The news has led to a significant short interest in the stock, with some participants suggesting that the low market cap makes it cheaper to buy out AIM than to pay for the use of Ampligen with Keytruda over the next 13 years.

Newcomers· Sep 1

The market is heavily influenced by manipulation and short sellers, but the stock is expected to "fly" and potentially reach prices above $0.5.
The company has big news, including a changing company value and an upcoming collaboration with Merck, which could be a major catalyst for the stock.
The stock has significant potential for a 1000% move, with many believing in its future success and encouraging others to buy in before a major price increase.

Generated by AI

AIM ImmunoTech

Social

Sep 3

Bullish· Sep 1

Bearish· Aug 31

Announcements· Jun 1

Technical Analysis· Jun 1

Regulars· Aug 31

Newcomers· Sep 1

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Aim ImmunoTech CEO Equels buys $4,992 in stock

Aim ImmunoTech CEO & president buys $2,310 in company stock

Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock

AIM ImmunoTech Reduces Debt via Equity Exchange Agreements

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

Also Discussed

AIM ImmunoTech Inc.

Company Information

Location

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Aim ImmunoTech CEO Equels buys $4,992 in stock

Aim ImmunoTech CEO & president buys $2,310 in company stock

Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock

AIM ImmunoTech Reduces Debt via Equity Exchange Agreements

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

Also Discussed

Social

Sep 3

Bullish· Sep 1

Bearish· Aug 31

Announcements· Jun 1

Technical Analysis· Jun 1

Regulars· Aug 31

Newcomers· Sep 1